Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 44Terminated 10Recruiting 8Active not recruiting 8Unknown 3Withdrawn 2Not yet recruiting 2Suspended 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Breast Neoplasms 369Neoplasms 253Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 192Lung Neoplasms 140Colorectal Neoplasms 137Neoplasm Metastasis 132Pancreatic Neoplasms 131Leukemia, Myeloid, Acute 126Multiple Myeloma 122Lymphoma 114Carcinoma, Hepatocellular 111Ovarian Neoplasms 98Melanoma 97Recurrence 93Leukemia 88Head and Neck Neoplasms 88Leukemia, Lymphocytic, Chronic, B-Cell 86Brain Neoplasms 86Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Glioblastoma 77Lymphoma, Non-Hodgkin 73Squamous Cell Carcinoma of Head and Neck 71Lymphoma, Follicular 70Lymphoma, Large B-Cell, Diffuse 66Colonic Neoplasms 66Carcinoma, Renal Cell 61Hematologic Neoplasms 59Sarcoma 55Glioma 53

Interventions

oblimersen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Leukemia, Lymphoid × Clear all
NCT02556346 2016-03-02

Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Molecular Templates, Inc.

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphoid, Neoplasms, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00517218 2008-02-11

This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)

Genta Incorporated

Phase 3 Withdrawn
Other hematologic neoplasm

Leukemia, Lymphoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡